Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero-Bermejo, Antonio F., Darnaude-Ximénez, Ignacio, Aguilar-Pérez, Myriam, Gomez-Lopez, Alicia, Sancho-López, Aránzazu, López García-Gallo, Cristina, Díaz Nuevo, Gema, Diago-Sempere, Elena, Ruiz-Antorán, Belén, Avendaño-Solá, Cristina, Ussetti-Gil, Piedad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583689/
https://www.ncbi.nlm.nih.gov/pubmed/37787528
http://dx.doi.org/10.1128/aac.00613-23
Descripción
Sumario:Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.

Ejemplares similares